Skip to content

Revance Therapeutics, Inc.: financial reference

Explore Revance Therapeutics, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Filing record ends 2024-02-28

The latest filing in this captured record is a 10-K filed 2024-02-28. No later filing is in the SEC companyfacts record captured on 2026-09-21. Revance Therapeutics, Inc. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2023-12-31478,454,000USD2024-02-28
Total liabilitiesAt date2023-12-31630,058,000USD2024-02-28
Stockholders equityAt date2023-12-31-151,604,000USD2024-02-28
Cash and cash equivalentsAt date2023-12-31137,329,000USD2024-02-28
Net income or loss2023-01-012023-12-31-323,986,000USD2024-02-28
Operating cash flow2023-01-012023-12-31-216,575,000USD2024-02-28
Capital expenditure payments2023-01-012023-12-316,886,000USD2024-02-28
Revenue2019-01-012019-12-31413,000USD2020-02-26
Contract revenue excluding tax2023-01-012023-12-31234,040,000USD2024-02-28
Financing cash flow2023-01-012023-12-31136,567,000USD2024-02-28
Investing cash flow2023-01-012023-12-31109,740,000USD2024-02-28
Retained earnings or deficitAt date2023-12-31-2,078,360,000USD2024-02-28
Basic weighted-average shares2023-01-012023-12-3184,599,409shares2024-02-28
Diluted weighted-average shares2023-01-012023-12-3184,599,409shares2024-02-28
Basic earnings per share2023-01-012023-12-31-3.83USD/shares2024-02-28
Diluted earnings per share2023-01-012023-12-31-3.83USD/shares2024-02-28
Income tax expense or benefit2023-01-012023-12-31300,000USD2024-02-28
Net property, plant and equipmentAt date2023-12-3117,225,000USD2024-02-28
Share-based compensation expense2023-01-012023-12-3147,813,000USD2024-02-28
Operating income or loss2023-01-012023-12-31-316,777,000USD2024-02-28
Current assetsAt date2023-12-31338,865,000USD2024-02-28
Interest expense2023-01-012023-12-3119,356,000USD2024-02-28
Current liabilitiesAt date2023-12-3189,224,000USD2024-02-28
Current accounts payableAt date2023-12-3113,809,000USD2024-02-28
Goodwill carrying amountAt date2023-12-310USD2024-02-28
Net finite-lived intangible assetsAt date2023-12-319,808,000USD2024-02-28
Net current accounts receivableAt date2023-12-3127,676,000USD2024-02-28
Operating expenses2019-01-012019-12-31164,872,000USD2020-02-26
Net inventoryAt date2023-12-3145,579,000USD2024-02-28
Selling, general and administrative expense2023-01-012023-12-31297,732,000USD2024-02-28
Research and development expense2023-01-012023-12-3179,410,000USD2024-02-28
Common shares outstandingAt date2023-12-3187,962,765shares2024-02-28
Cash including restricted cashAt date2023-12-31144,749,000USD2024-02-28
Accumulated other comprehensive income or lossAt date2023-12-3114,000USD2024-02-28
Operating lease right-of-use assetAt date2023-12-3153,167,000USD2024-02-28
Operating lease liabilityAt date2023-12-3146,688,000USD2024-02-28
Long-term debtAt date2023-12-31429,095,000USD2024-02-28
Gross property, plant and equipmentAt date2022-12-3150,731,000USD2023-02-28
Accumulated depreciation on property, plant and equipmentAt date2022-12-3128,592,000USD2023-02-28
Net intangible assets excluding goodwillAt date2023-12-319,808,000USD2024-02-28
Other noncurrent assetsAt date2023-12-31321,000USD2024-02-28
Other noncurrent liabilitiesAt date2023-12-312,835,000USD2024-02-28
Accrued current liabilitiesAt date2023-12-3153,824,000USD2024-02-28
Prepaid expenses and other current assetsAt date2023-12-3111,145,000USD2024-02-28
Current contract liabilitiesAt date2023-12-3110,737,000USD2024-02-28
Net deferred tax assetsAt date2023-12-3118,553,000USD2024-02-28
Comprehensive income or loss2023-01-012023-12-31-323,598,000USD2024-02-28
Net income available to common stockholders2023-01-012023-12-31-323,986,000USD2024-02-28
Depreciation expense2020-01-012020-12-3110,250,000USD2021-02-25
Depreciation, depletion and amortization2023-01-012023-12-3111,375,000USD2024-02-28
Amortization of intangible assets2023-01-012023-12-316,130,000USD2024-02-28
Other nonoperating income or expense2023-01-012023-12-31-838,000USD2024-02-28
Current income tax expense or benefit2023-01-012023-12-31300,000USD2024-02-28
Deferred income tax expense or benefit2022-01-012022-12-310USD2023-02-28
Interest paid, net2023-01-012023-12-3115,090,000USD2024-02-28
Proceeds from issuing common stock2023-01-012023-12-31100,183,000USD2024-02-28
Operating lease payments2023-01-012023-12-3112,078,000USD2024-02-28
Change in accounts receivable2023-01-012023-12-3116,338,000USD2024-02-28
Change in inventories2023-01-012023-12-3114,910,000USD2024-02-28
Change in accounts payable2023-01-012023-12-316,900,000USD2024-02-28

Filings

43 Revance Therapeutics, filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
Revance Therapeutics, Inc. / CIK 0001479290
Captured
2026-09-21T17:20:10.493Z
SEC response SHA-256
076b991a44fc13ae19e1119723bdc78b153314a59cf8c4c1e663921a0cf829cf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001479290.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))